Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Hezhe Lu^#¹, Shujing Liu^#², Gao Zhang^#³, Bin Wu¹, Yueyao Zhu¹, Dennie T Frederick⁴, Yi Hu⁵, Wenqun Zhong¹, Sergio Randell³, Norah Sadek³, Wei Zhang¹, Gang Chen¹, Chaoran Cheng⁶, Jingwen Zeng¹, Lawrence W Wu³, Jie Zhang⁶, Xiaoming Liu², Wei Xu⁷, Clemens Krepler³, Katrin Sproesser³, Min Xiao³, Benchun Miao⁴, Jianglan Liu³, Claire D Song¹, Jephrey Y Liu⁷, Giorgos C Karakousis⁸, Lynn M Schuchter⁷, Yiling Lu⁹, Gordon Mills⁹, Yusheng Cong¹⁰, Jonathan Chernoff¹¹, Jun Guo¹², Genevieve M Boland¹³, Ryan J Sullivan⁴, Zhi Wei⁶, Jeffrey Field¹⁴, Ravi K Amaravadi⁸, Keith T Flaherty⁴, Meenhard Herlyn^#¹⁵, Xiaowei Xu^#^{16

17}, Wei Guo^#¹⁸

Affiliations

¹ Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
³ Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA.
⁴ Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, USA.
⁵ Department of Biology, Drexel University, Philadelphia, Pennsylvania, 19104, USA.
⁶ Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey, 07102, USA.
⁷ Abramson Cancer Center and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
⁸ Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
⁹ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77054, USA.
¹⁰ Institute of Aging Research, Hangzhou Normal University School of Medicine, Hangzhou, China.
¹¹ Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA.
¹² Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, 100036, China.
¹³ Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA.
¹⁴ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
¹⁵ Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA. herlynm@wistar.org.
¹⁶ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. xug@mail.med.upenn.edu.
¹⁷ Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. xug@mail.med.upenn.edu.
¹⁸ Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. guowei@sas.upenn.edu.

^# Contributed equally.

PMID: 30532003
DOI: 10.1038/s41586-018-0814-7

Published Erratum

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Hezhe Lu et al. Nature. 2019 Jan.

. 2019 Jan;565(7738):E4.

doi: 10.1038/s41586-018-0814-7.

Authors

Affiliations

¹ Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
³ Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA.
⁴ Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, USA.
⁵ Department of Biology, Drexel University, Philadelphia, Pennsylvania, 19104, USA.
⁶ Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey, 07102, USA.
⁷ Abramson Cancer Center and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
⁸ Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
⁹ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77054, USA.
¹⁰ Institute of Aging Research, Hangzhou Normal University School of Medicine, Hangzhou, China.
¹¹ Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA.
¹² Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, 100036, China.
¹³ Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA.
¹⁴ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
¹⁵ Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA. herlynm@wistar.org.
¹⁶ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. xug@mail.med.upenn.edu.
¹⁷ Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. xug@mail.med.upenn.edu.
¹⁸ Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. guowei@sas.upenn.edu.

^# Contributed equally.

PMID: 30532003
DOI: 10.1038/s41586-018-0814-7

Abstract

In this Letter, two relevant references were omitted; see the accompanying Amendment for details. The original Letter has not been corrected.

PubMed Disclaimer

Erratum for

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Lu H, et al. Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27. Nature. 2017. PMID: 28953887 Free PMC article.

References

1. Singhal, R. & Kandel, E. S. The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. Oncotarget 3, 700–708 (2012). - DOI
1. Babagana, M. et al. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Mol. Carcinog. 56, 1515–1525 (2017). - DOI

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Affiliations

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Authors

Affiliations

Abstract

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials